DK0920429T3 - Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater - Google Patents

Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater

Info

Publication number: DK0920429T3
Authority: DK; Denmark
Prior art keywords: pyrimido; substituted pyrido; bicyclic derivatives; bicyclic; derivatives
Prior art date: 1996-08-06

Application number

DK97929472T

Other languages

Danish (da)

English (en)

Inventor

Yuhpyng Liang Chen

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-06

Filing date

1997-07-23

Publication date

2003-05-12

1997-07-23 Application filed by Pfizer filed Critical Pfizer

2003-05-12 Application granted granted Critical

2003-05-12 Publication of DK0920429T3 publication Critical patent/DK0920429T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Other In-Based Heterocyclic Compounds (AREA)

DK97929472T 1996-08-06 1997-07-23 Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater DK0920429T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2345396P	1996-08-06	1996-08-06
PCT/IB1997/000918 WO1998005661A1 (fr)	1996-08-06	1997-07-23	Derives 6,6- ou 6,7-bicycliques contenant pyrido ou pyrimido substitues

Publications (1)

Publication Number	Publication Date
DK0920429T3 true DK0920429T3 (da)	2003-05-12

Family

ID=21815208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97929472T DK0920429T3 (da)	1996-08-06	1997-07-23	Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater

Country Status (40)

Country	Link
US (1)	US6492520B1 (fr)
EP (1)	EP0920429B1 (fr)
JP (1)	JP3345021B2 (fr)
KR (1)	KR20000029843A (fr)
CN (1)	CN1093130C (fr)
AP (1)	AP1096A (fr)
AR (1)	AR008829A1 (fr)
AT (1)	ATE232863T1 (fr)
AU (1)	AU709203B2 (fr)
BG (1)	BG103143A (fr)
BR (1)	BR9710808A (fr)
CA (1)	CA2262692C (fr)
CO (1)	CO4900060A1 (fr)
CZ (1)	CZ292806B6 (fr)
DE (1)	DE69719193T2 (fr)
DK (1)	DK0920429T3 (fr)
DZ (1)	DZ2289A1 (fr)
EA (1)	EA003188B1 (fr)
ES (1)	ES2191183T3 (fr)
GT (1)	GT199700089A (fr)
HR (1)	HRP970432B1 (fr)
ID (1)	ID17980A (fr)
IL (1)	IL128188A0 (fr)
IS (1)	IS4948A (fr)
MA (1)	MA24296A1 (fr)
NO (1)	NO313293B1 (fr)
NZ (1)	NZ333727A (fr)
OA (1)	OA10970A (fr)
PA (1)	PA8435201A1 (fr)
PE (1)	PE97098A1 (fr)
PL (1)	PL331602A1 (fr)
SA (1)	SA97180334A (fr)
SK (1)	SK14099A3 (fr)
TN (1)	TNSN97135A1 (fr)
TR (1)	TR199900228T2 (fr)
TW (1)	TW550265B (fr)
UY (1)	UY24655A1 (fr)
WO (1)	WO1998005661A1 (fr)
YU (1)	YU5399A (fr)
ZA (1)	ZA976954B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
JP2003525201A (ja)	1998-08-20	2003-08-26	スミスクライン・ビーチャム・コーポレイション	新規な置換トリアゾール化合物
EP1129096B1 (fr)	1998-11-12	2003-05-21	Neurocrine Biosciences, Inc.	Antagonistes de recepteurs du crf et methodes associees
IL142893A0 (en)	1998-11-12	2002-04-21	Neurocrine Biosciences Inc	Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
US6432989B1 (en)	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
CO5271670A1 (es) *	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
CA2398956A1 (fr) *	2000-02-14	2001-08-16	Japan Tobacco Inc.	Composition pharmaceutique pour la prophylaxie ou le traitement du stress post-operatoire
WO2001062718A1 (fr) *	2000-02-25	2001-08-30	Japan Tobacco, Inc.	Dérivé de benzamide et utilisation de celui-ci
MY141144A (en) *	2000-03-02	2010-03-15	Smithkline Beecham Corp	1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en)	2000-05-18	2000-07-05	Suyal N	Thick glass films with controlled refractive indices and their applications
ATE521353T1 (de)	2000-10-23	2011-09-15	Glaxosmithkline Llc	Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
GB0117396D0 (en)	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
BR0212864A (pt)	2001-09-26	2004-08-17	Bayer Pharmaceuticals Corp	Derivados de 1,6-naftiridina como antidiabéticos
KR20040103972A (ko)	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
FR2846657B1 (fr) *	2002-11-05	2004-12-24	Servier Lab	Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
OA13309A (en)	2002-12-20	2007-04-13	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth.
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
NZ544472A (en)	2003-07-03	2009-04-30	Myriad Genetics Inc	Compounds and therapeutical use thereof
US8309562B2 (en)	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
US20050085479A1 (en) *	2003-08-27	2005-04-21	Pharmacia Corporation	Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
WO2005099688A2 (fr) *	2004-04-07	2005-10-27	Takeda Pharmaceutical Company Limited	Composes cycliques
MXPA06013165A (es)	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MXPA06013164A (es)	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2005111024A1 (fr)	2004-05-14	2005-11-24	Pfizer Products Inc.	Derives de pyrimidine destines au traitement de croissance cellulaire anormale
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
CA2592900A1 (fr)	2005-01-03	2006-07-13	Myriad Genetics Inc.	Composes et utilisation therapeutique associee
WO2006110298A2 (fr) *	2005-03-25	2006-10-19	Glaxo Group Limited	Nouveaux composes
UY29440A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
EP1865959A2 (fr)	2005-03-25	2007-12-19	Glaxo Group Limited	Procede de preparation de derives pyridoý2,3-d¨pyrimidin-7-one et 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one
UY29439A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
PT1888548E (pt)	2005-05-26	2012-10-30	Neuron Systems Inc	Derivado de quinolina para o tratamento de doenças da retina
EP1979348B1 (fr)	2005-12-21	2012-01-18	Abbott Laboratories	Composes antiviraux
ATE475660T1 (de)	2005-12-21	2010-08-15	Abbott Lab	Antivirale verbindungen
CN101443334A (zh) *	2005-12-21	2009-05-27	艾博特公司	抗病毒化合物
EP2345652A1 (fr)	2005-12-21	2011-07-20	Abbott Laboratories	Composées antivirales
US7915411B2 (en)	2005-12-21	2011-03-29	Abbott Laboratories	Anti-viral compounds
US8236950B2 (en)	2006-12-20	2012-08-07	Abbott Laboratories	Anti-viral compounds
ES2467108T3 (es)	2008-12-09	2014-06-11	Gilead Sciences, Inc.	Moduladores de receptores tipo toll
US8551996B2 (en) *	2009-02-20	2013-10-08	Emory University	Compounds, compositions, methods of synthesis, and methods of treatment
NO2477987T3 (fr)	2009-09-14	2018-06-09
WO2011072141A1 (fr)	2009-12-11	2011-06-16	Neuron Systems, Inc.	Compositions et procédés pour le traitement de la dégénérescence maculaire
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ES2704744T3 (es)	2012-06-13	2019-03-19	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
CA2898631C (fr)	2013-01-23	2023-06-13	Aldeyra Therapeutics, Inc.	Maladies liees a un aldehyde toxique et traitement
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
ES2761423T3 (es) *	2014-05-15	2020-05-19	Hoffmann La Roche	Compuestos para tratar la atrofia muscular espinal
US10882868B2 (en)	2014-05-15	2021-01-05	Hoffmann-La Roche Inc.	Compounds for treating spinal muscular atrophy
PT3166607T (pt)	2014-07-11	2022-12-07	Gilead Sciences Inc	Moduladores de receptores de tipo toll para o tratamento do vih
BR112017005100A2 (pt)	2014-09-16	2017-12-05	Gilead Sciences Inc	métodos de preparação de moduladores de receptores do tipo toll
CA2960436C (fr)	2014-09-16	2021-01-05	Gilead Sciences, Inc.	Formes solides d'un modulateur de recepteurs de type toll
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (fr)	2015-02-20	2016-08-25	Incyte Corporation	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es)	2015-02-20	2020-04-24	Incyte Holdings Corp	Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3317278B1 (fr)	2015-07-01	2021-04-14	Crinetics Pharmaceuticals, Inc.	Modulateurs de somatostatine et leurs utilisations
CN118724806A (zh)	2015-08-21	2024-10-01	奥尔德拉医疗公司	氘化化合物和其用途
BR112018016475A2 (en)	2016-02-12	2018-12-26	Cytokinetics, Incorporated	tetrahydroisoquinoline derivatives
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11028068B2 (en)	2017-07-25	2021-06-08	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
JP7311162B2 (ja) *	2017-10-10	2023-07-19	アルデイラセラピューティクス，インコーポレイテッド	炎症性障害の処置
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
CR20200590A (es)	2018-05-04	2021-04-26	Incyte Corp	Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
WO2020033344A1 (fr)	2018-08-06	2020-02-13	Aldeyra Therapeutics, Inc.	Composés polymorphes et leurs utilisations
EP3856478A4 (fr)	2018-09-25	2022-06-08	Aldeyra Therapeutics, Inc.	Formulations pour le traitement de la maladie de l'oeil sec
WO2020185532A1 (fr)	2019-03-08	2020-09-17	Incyte Corporation	Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
US11786518B2 (en)	2019-03-26	2023-10-17	Aldeyra Therapeutics, Inc.	Ophthalmic formulations and uses thereof
US12098132B2 (en)	2019-05-02	2024-09-24	Aldeyra Therapeutics, Inc.	Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh)	2019-05-02	2021-12-10	奥尔德拉医疗公司	多晶型化合物和其用途
WO2021007269A1 (fr)	2019-07-09	2021-01-14	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr)	2019-10-01	2021-04-08	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (fr)	2019-10-16	2021-04-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
EP4069696A1 (fr)	2019-12-04	2022-10-12	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr)	2020-01-15	2021-07-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CA3175856A1 (fr)	2020-05-13	2021-11-18	Todd Brady	Formulations pharmaceutiques et leurs utilisations
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022261159A1 (fr)	2021-06-09	2022-12-15	Incyte Corporation	Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
EP4352059A1 (fr)	2021-06-09	2024-04-17	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4605642A (en)	1984-02-23	1986-08-12	The Salk Institute For Biological Studies	CRF antagonists
US5063245A (en)	1990-03-28	1991-11-05	Nova Pharmaceutical Corporation	Corticotropin-releasing factor antagonism compounds
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
ATE177101T1 (de) *	1992-12-17	1999-03-15	Pfizer	Pyrrolopyrimidine als crf antagonisten
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
WO1995034563A1 (fr) *	1994-06-16	1995-12-21	Pfizer Inc.	Pyrazolo et pyrrolopyridines
JP2898887B2 (ja) *	1994-08-31	1999-06-02	沖電気工業株式会社	Ｉｃカードの読み取り装置
EP0729758A3 (fr) *	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
US6020492A (en) *	1995-05-12	2000-02-01	Neurogen Corporation	Deazapurine derivatives; a new class of CRF1 specific ligands
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
DE69628804T2 (de) *	1995-12-08	2003-12-18	Pfizer Inc., New York	Substitutierte heterozyclische Derivate als CRF Antagonisten
JP3356291B2 (ja)	1996-02-07	2002-12-16	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｃｒｆレセプター拮抗薬としてのピラゾロピリミジン類
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

1997
- 1997-07-23 US US09/242,076 patent/US6492520B1/en not_active Expired - Fee Related
- 1997-07-23 EP EP97929472A patent/EP0920429B1/fr not_active Expired - Lifetime
- 1997-07-23 TR TR1999/00228T patent/TR199900228T2/xx unknown
- 1997-07-23 AU AU33563/97A patent/AU709203B2/en not_active Ceased
- 1997-07-23 BR BR9710808A patent/BR9710808A/pt not_active Application Discontinuation
- 1997-07-23 KR KR1019997001005A patent/KR20000029843A/ko not_active Abandoned
- 1997-07-23 EA EA199900083A patent/EA003188B1/ru not_active IP Right Cessation
- 1997-07-23 DE DE69719193T patent/DE69719193T2/de not_active Expired - Fee Related
- 1997-07-23 NZ NZ333727A patent/NZ333727A/xx unknown
- 1997-07-23 WO PCT/IB1997/000918 patent/WO1998005661A1/fr not_active Ceased
- 1997-07-23 SK SK140-99A patent/SK14099A3/sk unknown
- 1997-07-23 PL PL97331602A patent/PL331602A1/xx unknown
- 1997-07-23 DK DK97929472T patent/DK0920429T3/da active
- 1997-07-23 AT AT97929472T patent/ATE232863T1/de not_active IP Right Cessation
- 1997-07-23 JP JP50775498A patent/JP3345021B2/ja not_active Expired - Fee Related
- 1997-07-23 YU YU5399A patent/YU5399A/sh unknown
- 1997-07-23 CA CA002262692A patent/CA2262692C/fr not_active Expired - Fee Related
- 1997-07-23 ES ES97929472T patent/ES2191183T3/es not_active Expired - Lifetime
- 1997-07-23 IL IL12818897A patent/IL128188A0/xx unknown
- 1997-07-23 CZ CZ1999411A patent/CZ292806B6/cs not_active IP Right Cessation
- 1997-07-23 CN CN97197079A patent/CN1093130C/zh not_active Expired - Fee Related
- 1997-07-31 AP APAP/P/1997/001052A patent/AP1096A/en active
- 1997-08-04 TW TW086111115A patent/TW550265B/zh active
- 1997-08-04 GT GT199700089A patent/GT199700089A/es unknown
- 1997-08-05 PA PA19978435201A patent/PA8435201A1/es unknown
- 1997-08-05 ID IDP972708A patent/ID17980A/id unknown
- 1997-08-05 CO CO97044966A patent/CO4900060A1/es unknown
- 1997-08-05 ZA ZA976954A patent/ZA976954B/xx unknown
- 1997-08-05 AR ARP970103560A patent/AR008829A1/es not_active Application Discontinuation
- 1997-08-05 PE PE1997000679A patent/PE97098A1/es not_active Application Discontinuation
- 1997-08-05 UY UY24655A patent/UY24655A1/es not_active IP Right Cessation
- 1997-08-06 DZ DZ970139A patent/DZ2289A1/fr active
- 1997-08-06 MA MA24755A patent/MA24296A1/fr unknown
- 1997-08-06 HR HR970432A patent/HRP970432B1/xx not_active IP Right Cessation
- 1997-08-06 TN TNTNSN97135A patent/TNSN97135A1/fr unknown
- 1997-08-25 SA SA97180334A patent/SA97180334A/ar unknown
1999
- 1999-01-19 IS IS4948A patent/IS4948A/is unknown
- 1999-02-03 OA OA9900024A patent/OA10970A/en unknown
- 1999-02-03 BG BG103143A patent/BG103143A/xx unknown
- 1999-02-05 NO NO19990544A patent/NO313293B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AR008829A1 (es)	2000-02-23
EP0920429A1 (fr)	1999-06-09
JP3345021B2 (ja)	2002-11-18
PE97098A1 (es)	1999-01-12
US6492520B1 (en)	2002-12-10
HRP970432B1 (en)	2002-10-31
HRP970432A2 (en)	1998-08-31
DE69719193T2 (de)	2003-09-25
AU709203B2 (en)	1999-08-26
ATE232863T1 (de)	2003-03-15
CN1227552A (zh)	1999-09-01
MA24296A1 (fr)	1998-04-01
ES2191183T3 (es)	2003-09-01
NO313293B1 (no)	2002-09-09
EA199900083A1 (ru)	1999-08-26
IL128188A0 (en)	1999-11-30
CA2262692C (fr)	2002-06-11
UY24655A1 (es)	2000-09-29
NZ333727A (en)	2000-09-29
DE69719193D1 (de)	2003-03-27
IS4948A (is)	1999-01-19
AP9701052A0 (en)	1997-10-31
WO1998005661A1 (fr)	1998-02-12
TNSN97135A1 (fr)	2005-03-15
CA2262692A1 (fr)	1998-02-12
TR199900228T2 (xx)	1999-03-22
KR20000029843A (ko)	2000-05-25
PL331602A1 (en)	1999-08-02
EP0920429B1 (fr)	2003-02-19
PA8435201A1 (es)	1999-12-27
NO990544L (no)	1999-03-31
JP2000501116A (ja)	2000-02-02
CN1093130C (zh)	2002-10-23
TW550265B (en)	2003-09-01
DZ2289A1 (fr)	2002-12-25
BR9710808A (pt)	1999-08-17
GT199700089A (es)	1999-01-26
EA003188B1 (ru)	2003-02-27
SK14099A3 (en)	2000-05-16
ZA976954B (en)	1999-02-05
OA10970A (en)	2001-11-05
BG103143A (en)	1999-09-30
AU3356397A (en)	1998-02-25
CO4900060A1 (es)	2000-03-27
CZ292806B6 (cs)	2003-12-17
AP1096A (en)	2002-08-26
SA97180334A (ar)	2005-12-03
NO990544D0 (no)	1999-02-05
YU5399A (sh)	2002-03-18
CZ41199A3 (cs)	2000-01-12
HK1021734A1 (en)	2000-06-30
ID17980A (id)	1998-02-12

Publication	Publication Date	Title
DK0920429T3 (da)	2003-05-12	Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
IS4963A (is)	1999-01-29	Setnar 6,5-heteró-bísýklískar afleiður
DK0925298T3 (da)	2004-08-09	Substituerede 6,6-heterobicykliske derivater
PT901474E (pt)	2006-07-31	Derivados de aril-pirimidina.
DK1000048T3 (da)	2003-03-03	Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE69718771D1 (de)	2003-03-06	Substituierte 1,2,3,4-tetrahydronaphthalinderivate
TR27961A (tr)	1995-11-06	Sübstitüe edilmis 1,2,3,4 -tetrahidro-5-nitro-pirimidinler.
TR199802520A3 (tr)	1999-06-21	1,3,8-Triaza-spiro(4,5) dekan -4-on türevleri.
DK1015467T3 (da)	2004-05-03	6,9-brobundne erythromycinderivater
ATE246199T1 (de)	2003-08-15	3-descladinose-2,3-anhydroerythromycin-derivate
DE69814441D1 (de)	2003-06-12	6,11-verbrückte erythromycinderivate
NL1005675A1 (nl)	1997-10-02	Polytriazinederivaten-bevattende polyalkylpiperidinyloxy- of polyalkylpiperidinylaminogroepen.
TR199700219A3 (tr)	1997-10-21	1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
ES1034273Y (es)	1997-05-01	Maleta-expositor transformable, perfeccionada.
TR199700927A3 (tr)	1999-03-22	N-Benzilazolyum türevleri.
SI0920429T1 (en)	2003-06-30	Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
FI962118A0 (fi)	1996-05-20	Foerbaettrad anordning foer behandling av roekgaser, saerskilt avgaser
ES1033065Y (es)	1996-12-16	Conjunto canula-tapa, perfeccionado.
ES1034802Y (es)	1997-07-01	Tope convertible en percha.
ITRC960004A0 (it)	1996-05-20	Vergafa m.c.